Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | AR Mato, SJ Schuster, N Lamanna, I Flinn, JC Barrientos, S Kambhampati, BD Cheson, PM Barr, JM Pagel, JA Reeves, F Lansigan, JJ Pu, AP Skarbnik, GA Fonseca, C Dorsey, EL Prak, D Paskalis, P Sportelli, HP Miskin, DM Brander | ||||||||||||
Title | A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K? inhibitor therapy. | ||||||||||||
|
|||||||||||||
URL | http://abstracts.asco.org/214/AbstView_214_223539.html | ||||||||||||
Abstract Text | J Clin Oncol 36, 2018 (suppl; abstr 7530) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|